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Abstract
Introduction: Vasculitis has been reported in a few cases of chronic lymphatic leukemia and with granulocytic
colony-stimulating factor therapy. Those with granulocytic colony-stimulating factor occurred after prolonged
therapy and there was a rise in total leukocyte count unlike that in our patient who received just a single injection
for the first time.
Case presentation: We report the case of a 64-year-old Egyptian man with chronic lymphatic leukemia who
developed progressive cutaneous vasculitic lesions following injection of a single dose of a granulocytic colony
stimulating factor before a third cycle of chemotherapy to improve neutropenia. This is an unusual case and the
pathogenesis is not fully understood. Our patient was not on any medical treatment except for bisoprolol for
ischemic heart disease. Although aggressive management with steroids, anticoagulation and plasmapheresis had
been carried out, the condition was aggressive and the patient’s consciousness deteriorated. A magnetic resonance
imaging scan of his brain revealed multiple ischemic foci that could be attributed to vasculitis of the brain.
Conclusion: The aim of this case report is to highlight the importance of monitoring patients on granulocytic
colony-stimulating factor therapy, especially in the context of other conditions (such as a hematological
malignancy) that may lead to an adverse outcome.
Introduction
An adverse reaction has been reported in rare cases with
granulocyte colony-stimulating factor treatment and in
patients with hematological malignancies. Here we pre-
sent a case of chronic lymphatic leukemia in which the
patient received just one injection of lenograstin for
neutropenia before starting the third cycle of che-
motherapy, in the absence of other medical conditions.
After the injection he developed cutaneous lesions and a
skin biopsy revealed vasculitis. The condition was severe
and the patient died 15 days after the onset of
symptoms.
Case presentation
A 64-year-old Egyptian man diagnosed with a case
of B-cell chronic lymphatic leukemia (CLL); Stage III
by RAI classification. He started a fludarabine and
cyclophosphamide regimen for two cycles that passed
smoothly. He was apparently healthy before the third
cycle. Lenograstin was given before the third cycle as
his TLC (total leukocyte count) was 2000/ul. After
subcutaneous injection redness occurred over the tip
of his nose, ears, hands and feet and within 48 hours
l e s i o n se x t e n d e do v e rh i sl e g sa n da r m s( F i g u r e s1 ,2 ,
3, 4, 5]. Steroids and LMWH (low molecular weight
heparin) were initiated; however, some red areas
became blackish. Due to the aggressiveness of the con-
dition daily plasmapheresis was performed, but without
clinical improvement. The patient’s level of conscious-
ness deteriorated progressively until he passed into a
deep coma and died five days after admission to the
intensive care unit (15 days after the onset of the con-
dition). Arterial and venous duplex were normal.
As k i nb i o p s yr e v e a l e dc o n f l uent necrosis in the epi-
dermis and infiltration of the dermis with lymphocytes
around the blood vessels, which were occluded by
fibrin plugs, a situation suggestive of vasculopathy * Correspondence: dr_noha2002@yahoo.com
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moglobin: 10 gm/dl, TLC 2000/ul(persistently) and
platelet count 150,000/ul. The immune screen for
cryoglobulins, cryofibrinogens, ANCA (antineutrophilic
cytoplasmic antibodies), cold agglutinin, ANA (anti-
neuclear antibodies), lupus anticoagulant and anticar-
diolipin were all negative. Tests revealed a PT
(prothrombin time) of 19 seconds, PC (prothrombin
concentration) of 56% INR (international normalized
ratio) as 1.7 and a PTT (partial thromboplastin time)
of 35 seconds. Fibrinogen repeatedly was normal. D
(domain) dimer, carried out at 72 hours, was 4000 ng/
ml. Protein electrophoresis showed hypoalbuminemia
with increased b globulin. C3 was normal but C4 was
consumed. No fragmented red blood cells (RBCs) were
seen in blood film. CRP(C reactive protein) was 0.5 (n
< 0.5), anti-HCV (anti hepatitis C virus antibodies) abs,
HBs antigen and HBc antibodies were all negative.
Serum viscosity was normal. Magnetic resonance ima-
ging (MRI) of the patient’s brain revealed age related
brain involutional changes and a few tiny bilateral cer-
ebral ischemic foci. Serum chemistry and electrolytes
were normal apart from mild hyponatremia of 130
mEq/L. His blood culture was negative.
Discussion
This case is considered unusual and the pathogenesis is
not fully understood as the described vasculitis does not
typically develop in this context with granulocytic col-
ony-stimulating factor (G-CSF) treatment. Cutaneous
vasculitis was reported in less than one in 7000 of those
treated with G-CSF, and was moderate to severe in inten-
sity. Most patients had severe chronic neutropenia and
were on long-term G-CSF therapy. Symptoms developed
with an increase in the absolute neutrophilic count
( A N C )a n ds t o p p e dw h e nt h eA N Cd e c r e a s e da n dt h e
patients continued treatment at a reduced dosage [1].
Regarding the association of vasculitis with hematological
malignancies, in a study done on 95 patients with hema-
t o l o g i c a lm a l i g n a n c yi tw a sf o u n dt h a t2 2 %h a dc u t a -
neous vasculitis, 39% developed it concomitantly with
malignancy, 26% of these before development of a malig-
nancy and 35% after diagnosis of a malignancy. In 61%
the vasculitis was explained only by the malignancy and
in the remaining 39% it was explained by other factors,
Figure 1 Vasculitic lesions on the leg during the first day after
lenograstin injection.
Figure 2 Vasculitic lesions on the hand in the second day.
Figure 3 Vasculitic lesions over the ear lobule.
Figure 4 Progression of vasulitic lesions on the lower limb
after 4 days.
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tions [2]. The association between lymphoma and vascu-
litis is rare in general. Lymphoproliferative disorders are
the most common hematological malignancies associated
with vasculitis (20%) especially hairy cell leukemia. Cases
of vasculitis with CLL are rare (0.1 to 2%) [3]. The
mechanisms of development of vasculitis in CLL include
1) immune complexes, 2) activation of B-lymphocytes, 3)
antibodies directed toward endothelial antigens, 4) the
direct effect of a malignancy on the vascular wall, 5)
adverse reactions to anticancer drugs, and 6) CD5-posi-
tive B cells present in CLL may produce auto antibodies
and monoclonal immunoglobulins with various autoanti-
body activities [4].
Conclusion
In conclusion, patients should be monitored for devel-
opment of inflammatory processes during G-CSF
therapy, which should be given with caution especially
in hematological malignancy situations.
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Figure 5 The legs after 10 days of onset of treatment.
Figure 6 Skin biopsy confluent necrosis in the epidermis.
Aggregates of lymphocytes perivascular. Intravascular fibrin clots.
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